

# Colorectal Cancer Screening Rates on the Rise Following Guideline Expansion

Team A: Brad Fox, MD; Brendan Joyce

Team B: Steve Allen, MD; Sam Sahakian

Last updated 10 March 2023 • Check for updates at [EpicResearch.org](https://EpicResearch.org)

## Key Findings:

- Overall, colorectal cancer screening rates increased from January 2018 through December 2022, largely due to a recent increase in screenings among 45–49-year-olds.
- During the same time period, colorectal cancer diagnosis rates decreased for those over age 50, driven mostly by a decrease in diagnoses in those over age 65.
- In the second quarter of 2021, national guidelines expanded to include colorectal cancer screening for 45–49-year-olds. For that age group, between Q2 2021 and Q4 2022, we observed:
  - Screening rates more than double.
  - Pre-cancerous polyp diagnosis rates more than double for females and triple for males.
  - Colorectal cancer diagnosis rates increase by half in males but no significant increase in females.

In May 2021, the U.S. Preventative Services Task Force (USPSTF) expanded its colorectal cancer screening recommendation to include all adults aged 45 to 49. This change required private insurance and Medicare to cover the costs of screening for the expanded population, per the Affordable Care Act (ACA).<sup>1,2</sup>

To further understand colorectal cancer screening and diagnosis rates and the potential influence of the expanded age range for screening, we reviewed records from 66,545,809 patients from 2018 through 2022. Colorectal cancer screening rates by age group and sex are shown in Figure 1. For the 45–49-year-old population, screening rates more than doubled following the change in screening guidelines and insurance coverage for colorectal cancer screening in 2021. Between Q2 of 2021 and Q4 of 2022, screenings increased from 3,386 per 100,000 patients to 8,068 per 100,000 patients in females and from 3,743 per 100,000 patients to 9,885 per 100,000 patients in males.

# Colorectal Cancer Screening Rates




Figure 1. Quarterly rates of colorectal cancer screening per 100,000 patients stratified by sex and age group. Patients under age 45 are not currently included in USPSTF's recommendation for colorectal cancer screenings.

Polyp diagnosis rates also increased during the same time period for 45–49-year-olds, as seen in Figure 2. Polyp diagnosis rates in this age group increased from 368 diagnoses per 100,000 patients to 954 diagnoses per 100,000 patients for females and increased from 471 diagnoses per 100,000 patients to 1,468 diagnoses per 100,000 patients for males.

## New Polyp Diagnosis Rates




Figure 2. Quarterly rates of new polyp diagnosis per 100,000 patients stratified by sex and age group.

Overall, the rate of colorectal cancer diagnosis decreased from 2018 to the end of 2022. This was largely driven by a decrease in colorectal cancer diagnosis rates in patients aged 65 and older, as seen in Figure 3, which aligns with previous reports by the National Cancer Institute and the American Cancer Society.<sup>3,4,5</sup> However, in the 45–49-year-old male population, the diagnosis rate has increased since the expansion of the screening recommendation, with a rate of 34 diagnoses per 100,000 patients in Q2 2021, compared to 51 diagnoses per 100,000 patients in Q4 2022. Our findings align with recent studies that suggest colorectal cancer diagnoses decreased from 2018 to 2020 and add to these findings by including data from 2021 and 2022.<sup>3,4,5</sup>

## New Colorectal Cancer Diagnosis Rates




Figure 3. Quarterly rates of new colorectal cancer diagnosis per 100,000 patients stratified by sex and age group. "New Colorectal Cancer Diagnosis Rates" 2023. EpicResearch

*These data come from Cosmos, a HIPAA-defined Limited Data Set of more than 183 million patients from 193 Epic organizations including 1,119 hospitals and more than 24,700 clinics, serving patients in all 50 states and Lebanon. This study was completed by two teams that worked independently, each composed of a clinician and research scientists. The two teams came to similar conclusions.*

## References

1. U.S. Preventive Services Task Force. Colorectal cancer: screening. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening>. Accessed January 24, 2023.
2. American Cancer Society. Insurance coverage for colorectal cancer screening. <https://www.cancer.org/cancer/colorectal-rectal-cancer/detection-diagnosis-staging/screening-coverage-laws.html>. Accessed January 24, 2023. <https://doi.org/10.3322/caac.21772>. Accessed 5 Mar. 2023.
3. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Colorectal and rectum: recent trends in SEER age-adjusted incidence rates, 2000-2019. [https://seer.cancer.gov/statistics-network/explorer/application.html?site=20&data\\_type=1&graph\\_type=2&compareBy=age\\_range&chk\\_age\\_range\\_1=1&chk\\_age\\_range\\_9=9&chk\\_age\\_range\\_141=141&chk\\_age\\_range\\_157=157&rate\\_type=2&sex=1&race=1&stage=101&advopt\\_precision=1&advopt\\_show\\_ci=on&hdn\\_view=0&advopt\\_show\\_apc=on&advopt\\_display=2#graphArea](https://seer.cancer.gov/statistics-network/explorer/application.html?site=20&data_type=1&graph_type=2&compareBy=age_range&chk_age_range_1=1&chk_age_range_9=9&chk_age_range_141=141&chk_age_range_157=157&rate_type=2&sex=1&race=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#graphArea). Accessed January 24, 2023.

4. Fedewa, Stacey A., et al. "Changes in Cancer Screening in the US during the COVID-19 Pandemic." JAMA Network Open, vol. 5, no. 6, 3 June 2022, p. e2215490, <https://doi.org/10.1001/jamanetworkopen.2022.15490>. Accessed 3 Aug. 2022.
5. Siegel, Rebecca L., et al. "Colorectal Cancer Statistics, 2023." CA: A Cancer Journal for Clinicians, Mar. 2023, American Cancer Society. <https://doi.org/10.3322/caac.21772>. Accessed on March 9, 2023.

## Data Definitions

Term	Definition
<b>Colorectal cancer screening</b>	<p>Billing Procedure Linked diagnosis of SNOMED CT 275978004 or 275979007; or ICD-10-CM Z12.11 or Z12.12.</p> <p>Or procedure with name matching "sigmoidoscopy", "colonoscopy", or "colonography".</p> <p>Or a multitarget stool DNA test result, indicated by LOINC code 77353-1 or 77354-9</p> <p>Or a fecal occult blood test result, indicated by LOINC code 14563-1, 14564-9, 14565-6, 2335-8, 27396-1, 29771-3, 50196-5, 57803-9, 58453-2, 57905-2, 56490-6, 56491-4, 80372-6, 12504-7, 27926-5, 27401-9, 12503-9, 27925-7</p>
<b>Colorectal cancer diagnosis</b>	Encounter or billing diagnosis with ICD-10-CM code in range C18 – C20
<b>Polyp diagnosis</b>	Encounter or billing diagnosis with ICD-10-CM code D12.0, D12.1, D12.2, D12.13, D12.4, D12.5, D12.6, D12.7, D12.8, or K63.5

**Table 1: Female Colorectal Cancer Screening Rates**

Year & Quarter	Age Group	Number of Screenings	Total Patient	Rate per Hundred Thousand
2017 Q1	<45	17,743	3,916,992	453.0
2017 Q1	45-49	6,197	502,139	1,234.1
2017 Q1	50-64	70,947	1,764,821	4,020.1
2017 Q1	65+	50,334	1,791,813	2,809.1
2017 Q2	<45	19,465	3,853,593	505.1
2017 Q2	45-49	6,627	504,806	1,312.8
2017 Q2	50-64	79,651	1,809,819	4,401.0
2017 Q2	65+	56,432	1,905,635	2,961.3
2017 Q3	<45	20,701	3,956,799	523.2
2017 Q3	45-49	6,697	510,084	1,312.9
2017 Q3	50-64	82,895	1,835,569	4,516.0
2017 Q3	65+	58,686	1,947,680	3,013.1
2017 Q4	<45	21,339	4,046,588	527.3
2017 Q4	45-49	6,981	525,548	1,328.3
2017 Q4	50-64	91,208	1,904,467	4,789.2
2017 Q4	65+	61,915	2,008,376	3,082.8
2018 Q1	<45	22,332	4,177,196	534.6

2018 Q1	45-49	7,493	536,556	1,396.5
2018 Q1	50-64	98,261	1,890,405	5,197.9
2018 Q1	65+	64,569	1,991,154	3,242.8
2018 Q2	<45	22,953	4,067,668	564.3
2018 Q2	45-49	8,522	537,657	1,585.0
2018 Q2	50-64	105,454	1,936,727	5,445.0
2018 Q2	65+	73,847	2,122,082	3,479.9
2018 Q3	<45	23,293	4,236,128	549.9
2018 Q3	45-49	9,294	545,317	1,704.3
2018 Q3	50-64	104,222	1,965,355	5,303.0
2018 Q3	65+	72,963	2,164,808	3,370.4
2018 Q4	<45	24,709	4,374,146	564.9
2018 Q4	45-49	9,794	568,932	1,721.5
2018 Q4	50-64	112,752	2,069,704	5,447.7
2018 Q4	65+	77,980	2,269,479	3,436.0
2019 Q1	<45	25,529	4,440,421	574.9
2019 Q1	45-49	10,112	570,023	1,774.0
2019 Q1	50-64	112,269	2,043,059	5,495.1
2019 Q1	65+	76,109	2,229,319	3,414.0
2019 Q2	<45	25,795	4,381,098	588.8
2019 Q2	45-49	10,897	570,557	1,909.9
2019 Q2	50-64	121,786	2,089,432	5,828.7
2019 Q2	65+	87,005	2,371,865	3,668.2
2019 Q3	<45	26,087	4,538,949	574.7
2019 Q3	45-49	10,899	576,030	1,892.1
2019 Q3	50-64	122,895	2,112,596	5,817.3
2019 Q3	65+	87,382	2,406,736	3,630.7
2019 Q4	<45	26,110	4,672,255	558.8
2019 Q4	45-49	10,993	590,638	1,861.2
2019 Q4	50-64	123,508	2,178,542	5,669.3
2019 Q4	65+	87,298	2,465,067	3,541.4
2020 Q1	<45	24,529	4,538,200	540.5
2020 Q1	45-49	10,429	573,035	1,820.0
2020 Q1	50-64	109,003	2,077,932	5,245.7
2020 Q1	65+	78,485	2,329,789	3,368.8
2020 Q2	<45	17,356	3,498,767	496.1
2020 Q2	45-49	6,216	477,037	1,303.0
2020 Q2	50-64	60,416	1,782,701	3,389.0
2020 Q2	65+	50,601	2,083,281	2,428.9
2020 Q3	<45	29,159	4,541,962	642.0
2020 Q3	45-49	11,947	584,466	2,044.1
2020 Q3	50-64	119,866	2,171,771	5,519.3
2020 Q3	65+	92,283	2,491,842	3,703.4
2020 Q4	<45	28,376	4,658,730	609.1
2020 Q4	45-49	13,398	605,233	2,213.7
2020 Q4	50-64	123,038	2,240,092	5,492.5
2020 Q4	65+	91,824	2,492,328	3,684.3
2021 Q1	<45	35,768	4,956,366	721.7
2021 Q1	45-49	15,425	659,535	2,338.8

2021 Q1	50-64	127,394	2,509,390	5,076.7
2021 Q1	65+	94,537	3,060,011	3,089.4
2021 Q2	<45	57,068	5,248,749	1,087.3
2021 Q2	45-49	21,837	644,931	3,385.9
2021 Q2	50-64	149,034	2,422,156	6,152.9
2021 Q2	65+	126,964	2,687,929	4,723.5
2021 Q3	<45	56,657	5,137,476	1,102.8
2021 Q3	45-49	30,343	603,869	5,024.8
2021 Q3	50-64	149,571	2,294,565	6,518.5
2021 Q3	65+	128,204	2,709,564	4,731.5
2021 Q4	<45	52,392	5,141,676	1,019.0
2021 Q4	45-49	35,668	615,649	5,793.6
2021 Q4	50-64	147,108	2,342,695	6,279.4
2021 Q4	65+	124,109	2,756,921	4,501.7
2022 Q1	<45	49,245	4,862,747	1,012.7
2022 Q1	45-49	41,985	600,061	6,996.8
2022 Q1	50-64	142,452	2,233,499	6,378.0
2022 Q1	65+	115,206	2,633,073	4,375.3
2022 Q2	<45	34,884	4,895,271	712.6
2022 Q2	45-49	47,799	605,427	7,895.1
2022 Q2	50-64	141,974	2,293,243	6,191.0
2022 Q2	65+	112,805	2,811,733	4,011.9
2022 Q3	<45	20,804	5,062,485	410.9
2022 Q3	45-49	47,193	615,052	7,673.0
2022 Q3	50-64	131,198	2,316,878	5,662.7
2022 Q3	65+	103,107	2,874,724	3,586.7
2022 Q4	<45	20,188	5,080,541	397.4
2022 Q4	45-49	49,324	611,326	8,068.4
2022 Q4	50-64	129,379	2,279,089	5,676.8
2022 Q4	65+	101,212	2,825,607	3,582.0

**Table 2: Male Colorectal Cancer Screening Rates**

Year & Quarter	Age Group	Number of Screenings	Total Patient	Rate per Hundred Thousand
2017 Q1	<45	11,369	2,819,615	403.2
2017 Q1	45-49	4,451	313,450	1,420.0
2017 Q1	50-64	60,333	1,260,422	4,786.7
2017 Q1	65+	39,370	1,293,601	3,043.4
2017 Q2	<45	12,219	2,779,149	439.7
2017 Q2	45-49	4,602	311,709	1,476.4
2017 Q2	50-64	63,707	1,273,623	5,002.0
2017 Q2	65+	43,757	1,368,346	3,197.8
2017 Q3	<45	12,358	2,894,975	426.9
2017 Q3	45-49	4,418	315,725	1,399.3
2017 Q3	50-64	65,113	1,289,865	5,048.0
2017 Q3	65+	44,596	1,393,433	3,200.4
2017 Q4	<45	12,870	2,925,200	440.0
2017 Q4	45-49	4,805	319,188	1,505.4
2017 Q4	50-64	72,987	1,324,469	5,510.7

2017 Q4	65+	48,039	1,444,931	3,324.7
2018 Q1	<45	14,114	3,008,365	469.2
2018 Q1	45-49	5,517	337,021	1,637.0
2018 Q1	50-64	81,460	1,358,427	5,996.6
2018 Q1	65+	51,328	1,452,841	3,532.9
2018 Q2	<45	14,009	2,918,522	480.0
2018 Q2	45-49	5,784	331,765	1,743.4
2018 Q2	50-64	83,308	1,368,362	6,088.2
2018 Q2	65+	56,763	1,533,371	3,701.8
2018 Q3	<45	14,568	3,098,702	470.1
2018 Q3	45-49	6,491	339,185	1,913.7
2018 Q3	50-64	82,433	1,391,176	5,925.4
2018 Q3	65+	56,123	1,561,118	3,595.1
2018 Q4	<45	15,316	3,171,315	483.0
2018 Q4	45-49	6,907	351,313	1,966.1
2018 Q4	50-64	92,118	1,461,328	6,303.7
2018 Q4	65+	60,059	1,645,554	3,649.8
2019 Q1	<45	15,799	3,201,620	493.5
2019 Q1	45-49	7,604	360,240	2,110.8
2019 Q1	50-64	96,096	1,482,690	6,481.2
2019 Q1	65+	60,628	1,637,133	3,703.3
2019 Q2	<45	16,194	3,170,757	510.7
2019 Q2	45-49	7,659	356,354	2,149.3
2019 Q2	50-64	98,338	1,494,774	6,578.8
2019 Q2	65+	66,630	1,730,354	3,850.7
2019 Q3	<45	16,342	3,348,302	488.1
2019 Q3	45-49	7,410	361,507	2,049.8
2019 Q3	50-64	98,415	1,513,442	6,502.7
2019 Q3	65+	67,190	1,757,098	3,823.9
2019 Q4	<45	16,312	3,423,815	476.4
2019 Q4	45-49	7,950	367,542	2,163.0
2019 Q4	50-64	101,674	1,549,613	6,561.3
2019 Q4	65+	69,070	1,805,552	3,825.4
2020 Q1	<45	15,572	3,303,457	471.4
2020 Q1	45-49	7,623	364,313	2,092.4
2020 Q1	50-64	95,531	1,521,694	6,277.9
2020 Q1	65+	63,630	1,733,908	3,669.7
2020 Q2	<45	10,601	2,433,415	435.6
2020 Q2	45-49	4,377	305,201	1,434.1
2020 Q2	50-64	50,628	1,321,921	3,829.9
2020 Q2	65+	41,064	1,585,343	2,590.2
2020 Q3	<45	18,565	3,277,155	566.5
2020 Q3	45-49	8,591	366,820	2,342.0
2020 Q3	50-64	96,590	1,555,280	6,210.5
2020 Q3	65+	72,964	1,839,543	3,966.4
2020 Q4	<45	18,440	3,334,687	553.0
2020 Q4	45-49	10,078	380,851	2,646.2
2020 Q4	50-64	101,594	1,600,474	6,347.7
2020 Q4	65+	73,542	1,848,756	3,977.9

2021 Q1	<45	22,661	3,496,835	648.0
2021 Q1	45-49	12,146	434,447	2,795.7
2021 Q1	50-64	109,523	1,888,850	5,798.4
2021 Q1	65+	77,618	2,349,908	3,303.0
2021 Q2	<45	34,911	3,953,909	882.9
2021 Q2	45-49	16,420	438,718	3,742.7
2021 Q2	50-64	123,944	1,825,799	6,788.5
2021 Q2	65+	98,872	1,987,150	4,975.6
2021 Q3	<45	35,027	3,838,498	912.5
2021 Q3	45-49	23,308	387,462	6,015.6
2021 Q3	50-64	122,934	1,653,699	7,433.9
2021 Q3	65+	100,134	1,988,593	5,035.4
2021 Q4	<45	32,277	3,809,484	847.3
2021 Q4	45-49	27,110	393,215	6,894.4
2021 Q4	50-64	123,804	1,689,858	7,326.3
2021 Q4	65+	97,895	2,034,166	4,812.5
2022 Q1	<45	31,313	3,509,372	892.3
2022 Q1	45-49	32,964	380,547	8,662.3
2022 Q1	50-64	123,124	1,624,291	7,580.2
2022 Q1	65+	93,486	1,964,666	4,758.4
2022 Q2	<45	23,525	3,548,711	662.9
2022 Q2	45-49	36,152	379,678	9,521.8
2022 Q2	50-64	115,967	1,641,732	7,063.7
2022 Q2	65+	89,574	2,080,192	4,306.0
2022 Q3	<45	15,142	3,740,716	404.8
2022 Q3	45-49	35,960	387,703	9,275.1
2022 Q3	50-64	106,876	1,657,375	6,448.5
2022 Q3	65+	81,027	2,119,560	3,822.8
2022 Q4	<45	14,703	3,742,177	392.9
2022 Q4	45-49	37,340	377,759	9,884.6
2022 Q4	50-64	106,136	1,611,644	6,585.6
2022 Q4	65+	81,041	2,082,561	3,891.4

**Table 3: Female Polyp Diagnosis Rates**

Year & Quarter	Age Group	Polyp Diagnosis	Rate per Hundred Thousand
2018 Q1	<45	2,067	49.5
2018 Q1	45-49	1,409	262.6
2018 Q1	50-64	15,142	801.0
2018 Q1	65+	12,328	619.1
2018 Q2	<45	2,147	52.8
2018 Q2	45-49	1,437	267.3
2018 Q2	50-64	16,355	844.5
2018 Q2	65+	13,660	643.7
2018 Q3	<45	2,079	49.1
2018 Q3	45-49	1,458	267.4
2018 Q3	50-64	15,800	803.9
2018 Q3	65+	13,328	615.7
2018 Q4	<45	2,348	53.7

2018 Q4	45-49	1,695	297.9
2018 Q4	50-64	17,981	868.8
2018 Q4	65+	13,745	605.6
2019 Q1	<45	2,261	50.9
2019 Q1	45-49	1,625	285.1
2019 Q1	50-64	17,010	832.6
2019 Q1	65+	14,504	650.6
2019 Q2	<45	2,384	54.4
2019 Q2	45-49	1,727	302.7
2019 Q2	50-64	17,050	816.0
2019 Q2	65+	15,003	632.5
2019 Q3	<45	2,263	49.9
2019 Q3	45-49	1,719	298.4
2019 Q3	50-64	17,630	834.5
2019 Q3	65+	15,088	626.9
2019 Q4	<45	2,449	52.4
2019 Q4	45-49	1,829	309.7
2019 Q4	50-64	18,492	848.8
2019 Q4	65+	14,714	596.9
2020 Q1	<45	2,191	48.3
2020 Q1	45-49	1,486	259.3
2020 Q1	50-64	15,041	723.8
2020 Q1	65+	12,911	554.2
2020 Q2	<45	1,381	39.5
2020 Q2	45-49	955	200.2
2020 Q2	50-64	7,034	394.6
2020 Q2	65+	6,880	330.2
2020 Q3	<45	2,475	54.5
2020 Q3	45-49	1,853	317.0
2020 Q3	50-64	16,008	737.1
2020 Q3	65+	14,180	569.1
2020 Q4	<45	2,787	59.8
2020 Q4	45-49	1,974	326.2
2020 Q4	50-64	17,718	790.9
2020 Q4	65+	14,219	570.5
2021 Q1	<45	2,943	59.4
2021 Q1	45-49	2,221	336.8
2021 Q1	50-64	17,107	681.7
2021 Q1	65+	13,510	441.5
2021 Q2	<45	3,013	57.4
2021 Q2	45-49	2,371	367.6
2021 Q2	50-64	18,971	783.2
2021 Q2	65+	16,672	620.3
2021 Q3	<45	2,612	50.8
2021 Q3	45-49	2,667	441.7
2021 Q3	50-64	18,021	785.4
2021 Q3	65+	16,083	593.6
2021 Q4	<45	2,796	54.4
2021 Q4	45-49	3,358	545.4

2021 Q4	50-64	18,219	777.7
2021 Q4	65+	15,790	572.7
2022 Q1	<45	2,871	59.0
2022 Q1	45-49	3,967	661.1
2022 Q1	50-64	17,126	766.8
2022 Q1	65+	15,055	571.8
2022 Q2	<45	3,150	64.3
2022 Q2	45-49	4,817	795.6
2022 Q2	50-64	18,707	815.7
2022 Q2	65+	16,969	603.5
2022 Q3	<45	3,077	60.8
2022 Q3	45-49	5,094	828.2
2022 Q3	50-64	18,296	789.7
2022 Q3	65+	16,695	580.8
2022 Q4	<45	3,126	61.5
2022 Q4	45-49	5,835	954.5
2022 Q4	50-64	18,253	800.9
2022 Q4	65+	15,901	562.7

**Table 4: Male Polyp Diagnosis Rates**

Year & Quarter	Age Group	Polyp Diagnosis	Rate per Hundred Thousand
2018 Q1	<45	1,798	59.8
2018 Q1	45-49	1,224	363.2
2018 Q1	50-64	16,185	1,191.5
2018 Q1	65+	12,332	848.8
2018 Q2	<45	1,695	58.1
2018 Q2	45-49	1,226	369.5
2018 Q2	50-64	16,321	1,192.7
2018 Q2	65+	13,497	880.2
2018 Q3	<45	1,654	53.4
2018 Q3	45-49	1,299	383.0
2018 Q3	50-64	15,616	1,122.5
2018 Q3	65+	12,811	820.6
2018 Q4	<45	1,742	54.9
2018 Q4	45-49	1,435	408.5
2018 Q4	50-64	18,193	1,245.0
2018 Q4	65+	13,562	824.2
2019 Q1	<45	1,842	57.5
2019 Q1	45-49	1,626	451.4
2019 Q1	50-64	18,367	1,238.8
2019 Q1	65+	14,505	886.0
2019 Q2	<45	1,917	60.5
2019 Q2	45-49	1,432	401.8
2019 Q2	50-64	17,767	1,188.6
2019 Q2	65+	14,668	847.7
2019 Q3	<45	1,950	58.2
2019 Q3	45-49	1,354	374.5
2019 Q3	50-64	17,370	1,147.7
2019 Q3	65+	14,498	825.1
2019 Q4	<45	2,046	59.8

2019 Q4	45-49	1,543	419.8
2019 Q4	50-64	18,639	1,202.8
2019 Q4	65+	14,543	805.5
2020 Q1	<45	1,861	56.3
2020 Q1	45-49	1,415	388.4
2020 Q1	50-64	16,286	1,070.3
2020 Q1	65+	12,825	739.7
2020 Q2	<45	1,107	45.5
2020 Q2	45-49	777	254.6
2020 Q2	50-64	7,397	559.6
2020 Q2	65+	7,223	455.6
2020 Q3	<45	1,984	60.5
2020 Q3	45-49	1,448	394.7
2020 Q3	50-64	15,995	1,028.4
2020 Q3	65+	13,759	748.0
2020 Q4	<45	2,202	66.0
2020 Q4	45-49	1,825	479.2
2020 Q4	50-64	17,790	1,111.5
2020 Q4	65+	13,463	728.2
2021 Q1	<45	2,491	71.2
2021 Q1	45-49	2,063	474.9
2021 Q1	50-64	18,019	954.0
2021 Q1	65+	13,673	581.9
2021 Q2	<45	2,442	61.8
2021 Q2	45-49	2,066	470.9
2021 Q2	50-64	18,858	1,032.9
2021 Q2	65+	16,229	816.7
2021 Q3	<45	2,184	56.9
2021 Q3	45-49	2,323	599.5
2021 Q3	50-64	17,714	1,071.2
2021 Q3	65+	15,429	775.9
2021 Q4	<45	2,303	60.5
2021 Q4	45-49	3,147	800.3
2021 Q4	50-64	18,392	1,088.4
2021 Q4	65+	14,981	736.5
2022 Q1	<45	2,446	69.7
2022 Q1	45-49	3,998	1,050.6
2022 Q1	50-64	18,301	1,126.7
2022 Q1	65+	15,047	765.9
2022 Q2	<45	2,602	73.3
2022 Q2	45-49	4,444	1,170.5
2022 Q2	50-64	18,726	1,140.6
2022 Q2	65+	16,046	771.4
2022 Q3	<45	2,317	61.9
2022 Q3	45-49	4,998	1,289.1
2022 Q3	50-64	17,727	1,069.6
2022 Q3	65+	15,777	744.4
2022 Q4	<45	2,442	65.3
2022 Q4	45-49	5,544	1,467.6

2022 Q4	50-64	18,162	1,126.9
2022 Q4	65+	15,074	723.8

**Table 5: Female Colorectal Cancer Diagnosis Rates**

Year & Quarter	Age Group	Colorectal Cancer Diagnosis	Rate per Hundred Thousand
2018 Q1	<45	174	4.2
2018 Q1	45-49	137	25.5
2018 Q1	50-64	841	44.5
2018 Q1	65+	1,748	87.8
2018 Q2	<45	184	4.5
2018 Q2	45-49	135	25.1
2018 Q2	50-64	938	48.4
2018 Q2	65+	1,928	90.9
2018 Q3	<45	183	4.3
2018 Q3	45-49	156	28.6
2018 Q3	50-64	900	45.8
2018 Q3	65+	1,852	85.6
2018 Q4	<45	173	4.0
2018 Q4	45-49	137	24.1
2018 Q4	50-64	928	44.8
2018 Q4	65+	2,010	88.6
2019 Q1	<45	186	4.2
2019 Q1	45-49	145	25.4
2019 Q1	50-64	993	48.6
2019 Q1	65+	1,997	89.6
2019 Q2	<45	172	3.9
2019 Q2	45-49	143	25.1
2019 Q2	50-64	970	46.4
2019 Q2	65+	2,044	86.2
2019 Q3	<45	194	4.3
2019 Q3	45-49	153	26.6
2019 Q3	50-64	1,022	48.4
2019 Q3	65+	2,150	89.3
2019 Q4	<45	185	4.0
2019 Q4	45-49	164	27.8
2019 Q4	50-64	988	45.4
2019 Q4	65+	2,105	85.4
2020 Q1	<45	219	4.8
2020 Q1	45-49	116	20.2
2020 Q1	50-64	923	44.4
2020 Q1	65+	1,962	84.2
2020 Q2	<45	149	4.3
2020 Q2	45-49	119	24.9
2020 Q2	50-64	651	36.5
2020 Q2	65+	1,486	71.3
2020 Q3	<45	203	4.5
2020 Q3	45-49	150	25.7
2020 Q3	50-64	922	42.5

2020 Q3	65+	2,036	81.7
2020 Q4	<45	184	3.9
2020 Q4	45-49	140	23.1
2020 Q4	50-64	891	39.8
2020 Q4	65+	1,933	77.6
2021 Q1	<45	196	4.0
2021 Q1	45-49	159	24.1
2021 Q1	50-64	924	36.8
2021 Q1	65+	1,952	63.8
2021 Q2	<45	208	4.0
2021 Q2	45-49	162	25.1
2021 Q2	50-64	947	39.1
2021 Q2	65+	2,195	81.7
2021 Q3	<45	190	3.7
2021 Q3	45-49	164	27.2
2021 Q3	50-64	923	40.2
2021 Q3	65+	2,100	77.5
2021 Q4	<45	185	3.6
2021 Q4	45-49	158	25.7
2021 Q4	50-64	939	40.1
2021 Q4	65+	1,966	71.3
2022 Q1	<45	222	4.6
2022 Q1	45-49	174	29.0
2022 Q1	50-64	928	41.5
2022 Q1	65+	1,874	71.2
2022 Q2	<45	243	5.0
2022 Q2	45-49	191	31.5
2022 Q2	50-64	978	42.6
2022 Q2	65+	2,182	77.6
2022 Q3	<45	202	4.0
2022 Q3	45-49	166	27.0
2022 Q3	50-64	976	42.1
2022 Q3	65+	2,081	72.4
2022 Q4	<45	214	4.2
2022 Q4	45-49	184	30.1
2022 Q4	50-64	960	42.1
2022 Q4	65+	1,906	67.5

**Table 6: Male Colorectal Cancer Diagnosis Rates**

Year & Quarter	Age Group	Colorectal Cancer Diagnosis	Rate per Hundred Thousand
2018 Q1	<45	166	5.5
2018 Q1	45-49	136	40.4
2018 Q1	50-64	955	70.3
2018 Q1	65+	1,651	113.6
2018 Q2	<45	145	5.0
2018 Q2	45-49	143	43.1
2018 Q2	50-64	990	72.3
2018 Q2	65+	1,767	115.2

2018 Q3	<45	167	5.4
2018 Q3	45-49	139	41.0
2018 Q3	50-64	944	67.9
2018 Q3	65+	1,745	111.8
2018 Q4	<45	151	4.8
2018 Q4	45-49	134	38.1
2018 Q4	50-64	1,015	69.5
2018 Q4	65+	1,909	116.0
2019 Q1	<45	158	4.9
2019 Q1	45-49	146	40.5
2019 Q1	50-64	1,099	74.1
2019 Q1	65+	1,948	119.0
2019 Q2	<45	172	5.4
2019 Q2	45-49	139	39.0
2019 Q2	50-64	1,067	71.4
2019 Q2	65+	1,981	114.5
2019 Q3	<45	184	5.5
2019 Q3	45-49	147	40.7
2019 Q3	50-64	1,066	70.4
2019 Q3	65+	2,064	117.5
2019 Q4	<45	161	4.7
2019 Q4	45-49	143	38.9
2019 Q4	50-64	1,128	72.8
2019 Q4	65+	1,924	106.6
2020 Q1	<45	152	4.6
2020 Q1	45-49	146	40.1
2020 Q1	50-64	1,083	71.2
2020 Q1	65+	1,827	105.4
2020 Q2	<45	134	5.5
2020 Q2	45-49	118	38.7
2020 Q2	50-64	825	62.4
2020 Q2	65+	1,500	94.6
2020 Q3	<45	202	6.2
2020 Q3	45-49	162	44.2
2020 Q3	50-64	1,067	68.6
2020 Q3	65+	1,934	105.1
2020 Q4	<45	167	5.0
2020 Q4	45-49	161	42.3
2020 Q4	50-64	1,059	66.2
2020 Q4	65+	1,802	97.5
2021 Q1	<45	192	5.5
2021 Q1	45-49	146	33.6
2021 Q1	50-64	1,037	54.9
2021 Q1	65+	1,807	76.9
2021 Q2	<45	199	5.0
2021 Q2	45-49	150	34.2
2021 Q2	50-64	1,118	61.2
2021 Q2	65+	2,059	103.6
2021 Q3	<45	191	5.0

2021 Q3	45-49	158	40.8
2021 Q3	50-64	1,066	64.5
2021 Q3	65+	1,940	97.6
2021 Q4	<45	194	5.1
2021 Q4	45-49	157	39.9
2021 Q4	50-64	1,003	59.4
2021 Q4	65+	1,799	88.4
2022 Q1	<45	196	5.6
2022 Q1	45-49	184	48.4
2022 Q1	50-64	1,086	66.9
2022 Q1	65+	1,878	95.6
2022 Q2	<45	171	4.8
2022 Q2	45-49	190	50.0
2022 Q2	50-64	1,167	71.1
2022 Q2	65+	2,061	99.1
2022 Q3	<45	193	5.2
2022 Q3	45-49	190	49.0
2022 Q3	50-64	1,070	64.6
2022 Q3	65+	1,957	92.3
2022 Q4	<45	197	5.3
2022 Q4	45-49	194	51.4
2022 Q4	50-64	1,097	68.1
2022 Q4	65+	1,781	85.5